UPDATE: Stifel Nicolaus Initiates Johnson & Johnson at Hold; Fairly Valued
Stifel Nicolaus initiated coverage on Johnson & Johnson (NYSE: JNJ) with a Hold rating.
Stifel Nicolaus noted, "We are initiating coverage of Johnson & Johnson (JNJ) with a Hold rating. We see JNJ as a core health care holding and total return vehicle in any environment for investors looking for safety and stability, particularly in these uncertain times. As JNJ continues to resolve recent issues and ex-FX sales growth reaccelerates modestly in each year over the next few years, JNJ shares should sustain its 12.6x forward P/E multiple, in line with the S&P 500."
Johnson & Johnson closed at $69.19 on Monday.
Latest Ratings for JNJ
|May 2016||Standpoint Research||Initiates Coverage on||Sell|
|May 2016||BTIG Research||Downgrades||Buy||Neutral|
|May 2016||Credit Suisse||Maintains||Neutral|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.